It was approved by the FDA for treating basal-cell carcinoma in July 2015[REF][REF] and is awaiting approval in the EU.
It is indicated for the treatment of adult patients with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy [REF].